Bortezomib Recruiting Phase 2 Trials for Cancer - Multiple Myeloma / Multiple Myeloma (MM) Treatment

RecruitingTreatment2 IdentifierTitleDrugs
NCT03314181A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04151667Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
NCT030042872015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
NCT03544281To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT02654990Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
NCT02188368Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
NCT01453088Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
NCT03412565A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03896737Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
NCT02977494Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
NCT02703779Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
NCT03188172MUK Nine b: OPTIMUM Treatment Protocol
NCT02086942Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.